Nanoform Finland plc announced that it has launched its sparse-data AI solution (STARMAP® Online) as a secure online portal for direct use by its current and future partners. Since its inception in 2020, STARMAP® has been actively used by Nanoform to provide its clients with a confident assessment of their molecules' suitability for Controlled Expansion of Supercritical Solutions (CESS®) nanoparticle engineering. STARMAP® is a digital version of the CESS® technology that enables in silico experiments to determine which molecules should be nanoformed. Nanoform's legacy processes involved handling all analyses in-house after receiving specific molecule attributes from its clients. STARMAP® Online has been launched as a direct request from Nanoform's current and future partners who seek to maintain the level of confidence STARMAP® offers, while integrating it into their own in-house molecule-selection processes. STARMAP® Online creates the opportunity for clients to perform large numbers of in-silico CESS® experiments from their desktop, prior to approaching Nanoform to perform experimental validation. This approach further supports Nanoform's green ambition by ensuring that Nanoform progresses the molecules with the greatest probability of success. STARMAP® Online offers increased user confidence through: Security and safety - the interface has been developed in alignment with ISO27001:2017 standards. Client submissions are seen only by clients (not by Nanoform), allowing molecules to be screened without sharing structures. Outputs are presented directly to the client via the system. Scalability and agility: The ability to manage thousands of molecules in a single submission to support the selection of candidates from molecule libraries is possible. Novel insights: STARMAP® Online holds a database of over 17,000 pre-analyzed, public-domain disclosed drugs and candidates. Clients can request thematic evaluations and understand the power of CESS® in different therapeutic areas, target classes, and disease areas.